Aquatic Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Aquatic Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,831	Closed	-$7.78M	–	1706
2025 Q3	$7.78M	Sell	13,831 -38,194	-73%	-$21.6M	0.14%	175
2025 Q2	$27.3M	Buy	52,025 +39,464	+314%	+$22M	0.55%	37
2025 Q1	$7.97M	Sell	12,561 -14,520	-54%	-$9.99M	0.2%	130
2024 Q4	$19.3M	Buy	27,081 +15,241	+129%	+$12.8M	0.52%	44
2024 Q3	$12.4M	Buy	+11,840	New	+$13.2M	0.33%	91
2024 Q1	–	Sell	-11,280	Closed	-$9.91M	–	1572
2023 Q4	$9.91M	Buy	+11,280	New	+$9.29M	0.25%	102
2023 Q2	–	Sell	-2,500	Closed	-$2.05M	–	1681
2023 Q1	$2.05M	Sell	2,500 -5,700	-70%	-$4.3M	0.13%	181
2022 Q4	$5.92M	Buy	+8,200	New	+$6.05M	0.43%	46
2022 Q1	–	Sell	-100	Closed	-$63K	–	1447
2021 Q4	$63K	Buy	+100	New	+$61.5K	0.12%	241

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Aquatic Capital Management's REGN Position: Q4 2025 in Review

Aquatic Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 13,831 shares — an estimated $7.78M sold.

Aquatic Capital Management first reported a position in REGN in Q4 2021 and held it in 9 quarters. The position peaked at $27.3M in Q2 2025. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

Aquatic Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Aquatic Capital Management sold 13,831 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $7.78M.
Aquatic Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Aquatic Capital Management's Regeneron Pharmaceuticals position peaked at $27.3M in Q2 2025.
1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Aquatic Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.